ABSTRACT. B-cell leukemia 11b (Bcl11b) is a zinc-finger transcription factor known as master regulator of T lymphocytes and neuronal development during embryogenesis. Bcl11b-interacting protein COUP-TFII is required for atrial development and vasculogenesis, however a role of Bcl11b in the adult cardiovascular system is unknown. A genome-wide association study (GWAS) recently showed that a gene desert region downstream of BCL11B and known to function as BCL11B enhancer harbors single nucleotide polymorphisms (SNPs) associated with increased arterial stiffness. Based on these human findings, we sought to examine relations between Bcl11b and arterial function using mice with Bcl11b deletion. We report for the first time that Bcl11b is expressed in vascular smooth muscle (VSM) and transcriptionally regulates the expression of VSM contractile proteins smooth muscle myosin and smooth muscle α-actin. Lack of Bcl11b in VSM-specific Bcl11b null mice (BSMKO) resulted in increased expression of Ca ++ -calmodulindependent serine/threonine phosphatase calcineurin in BSMKO VSM cells, cultured in serum-free condition, and in BSMKO aortas, which showed an inverse correlation with levels of phosphorylated VASP S239 , a regulator of cytoskeletal actin rearrangements. Moreover, decreased pVASP S239 in BSMKO aortas was associated with increased actin polymerization (F/G actin ratio).
INTRODUCTION.
A recent genome-wide association study (GWAS) of 9 discovery cohorts (20,634 participants; average age of cohort 34-75 years old) and 2 replication cohorts (N=5,306) identified single nucleotide polymorphisms (SNPs) in a gene desert locus on chromosome 14 with highly significant association (p < 5.6 x 10 -11 for the top SNP, rs1381289T>C) 1 with pulse wave velocity (PWV), the gold standard clinical measure of aortic wall stiffness 2 . Notably, the presence of each rs1381289 allele resulted in an estimated hazard ratio (HR) = 1.05 for a first major coronary artery disease event and HR = 1.10 for incident heart failure, suggesting that increased arterial stiffness associated with SNP variants in this locus may be causally linked to an increased risk of subsequently developing a major cardiovascular disease event.
The "aortic stiffness" locus spans 2 Mb between coding genes B-cell leukemia 11b
(BCL11B) and vaccinia-related kinase 1 (VRK1). A detailed analysis indicated that the region contains an ∼1.9 kb sequence, located ∼850 kb downstream (3') of BCL11B, known to function as an enhancer for BCL11B 3 but not VRK1. Enhancers are important DNA regulatory elements that activate the expression of target genes, independently of distance or orientation 4 . In addition, the long non-coding RNA (lncRNA) DB129663, of unknown biological function, partially overlaps with the BCL11B enhancer ( Figure 1 ). In the present study, we sought to elucidate the mechanistic basis of the association of the chromosome 14 locus with aortic stiffness and a possible causeeffect relationship between Bcl11b and vascular function.
Bcl11b, also known as COUP-TF interacting protein-2 (CTIP2), is a zinc finger transcription factor 5 best known as a regulator of T cell lineage commitment during hematopoiesis [6] [7] [8] and neuronal development during embryogenesis 9, 10 . However, a role of Bcl11b in the vasculature has never been described. Here we report for the first time that Bcl11b is expressed in 4 human and murine aortas and it is a crucial determinant of vascular smooth muscle (VSM) contractile phenotype, aortic wall stiffness and aortic structural integrity. Bcl11b transcriptionally regulates VSM-specific gene expression, including contractile proteins smooth muscle myosin and smooth muscle α-actin and the Ca ++ -calmodulin-dependent serine/threonine phosphatase calcineurin. Bcl11b deletion in VSM cells (BSMKO mice) resulted in increased actin polymerization (F/G actin ratio), increased baseline aortic tone and increased PWV compared to WT littermates. No significant blood pressure differences were noted between WT and BSMKO mice at baseline or upon ang II administration. However, 2-week ang II treatment induced aortic aneurysms in BSMKO mice with a ∼ 70% incidence. Taken together, our study identifies VSM Bcl11b as a novel and crucial regulator of VSM functional and structural integrity. Bcl11b
represents a promising candidate for the translational development of therapies against arterial stiffness, a major risk factor for cardiovascular disease, and aortic aneurysms.
METHODS.
Mice with VSM-specific Bcl11b deletion. Animal studies were approved by the Boston University Medical Center Institutional Animal Care and Use Committee (IACUC) in accordance with federal regulations and guidelines on the humane use of experimental animals. The Jackson Laboratory) to generate mice with constitutive Bcl11b deletion in VSM (SM22α-Cre + /Bcl11b flox/flox and SM22α-Cre -/Bcl11b flox/flox littermate controls), as we previously described 11, 12 . Mice were backcrossed into C57Bl/6J genetic background for at least 10 generations.
In vivo arterial stiffness measurements. Pulse wave velocity (PWV), the gold standard in vivo measure of aortic wall stiffness, was measured in (1) 10-months old WT (n=4) and global Bcl11b-deficient mice (n=4), and (2) WT (n=14) and VSM-specific Bcl11b-null mice (n=17; 9 BSMKO, 2 months after tamoxifen administration, and 8 SM22αBKO, at 2 months of age), by methods that we described previously [11] [12] [13] [14] [15] . Briefly, mice were kept recumbent and lightly anesthetized with 1-2% isofluorane while on a heated platform that maintained body temperature during the procedure.
Pressure or flow pressure waves and simultaneous electrocardiogram (ECG) were obtained from two locations along the aorta, using a dual-pressure high-fidelity pressure transducer (Mikro-tip catheter transducers, SPR-1000, Millar Instruments, Houston, TX, USA) interfaced with an acquisition and analysis workstation (NIHem, Cardiovascular Engineering, Norwood, MA, USA) 6 or high-resolution Doppler ultrasound (Vevo2100, Fujifilm Visualsonics, Toronto, Canada).
Arrival times of the pressure or flow waves at proximal and distal locations were measured by the foot-to-foot method using the R-wave of the ECG as fiducial point, on at least 5 cardiac cycles for each mouse. PWV was calculated as a ratio of the distance and the difference in arrival times of pressure or flow waves at the two locations (m/s). The investigator performing PWV measurements and post-acquisition calculations was blinded to mice genotype. We previously optimized PWV measurements in mice so that mean arterial pressure (MAP = 95 ± 5 mmHg) and heart rate (HR = 450 ± 50 bpm) are maintained constant and at comparable levels between mice 11-15 because PWV is dependent on both distending pressure (MAP) and heart rate 16 . However, in initial experiments with global Bcl11b-deficient mice, we intentionally increased MAP by jugular vein infusions of phenylephrine (100 µl, 10 µg/ml) in order to measure PWV over a range of MAP 80-140 mmHg to exclude any possible cofounding effects of MAP on PWV.
Isometric tension measurements of aortic rings from WT (n=5) and BSMKO (n=7) mice were performed as we previously described 14, 17, 18 . Briefly, aortic rings (∼ 4 mm axial length) were mounted on triangular wires attached to a force transducer, which recorded vessel wall tension.
Each ring was stretched to optimal length L O (1.8 × slack length) 18 Thirty µg of VSM cell or aortic proteins were resolved by SDS-PAGE in 4-15% polyacrylamide gels (100V, 60 min) and transferred to PVDF membranes (130 mA, 120 min).
Membranes were blocked in 5% non-fat milk in 1% Tween-20 in TBS (TBS-T) for 1 hour and incubated overnight with one of following antibodies at 1:1000 or 1:5000 dilution: Bcl11b 
Data availability.
Data supporting the findings of this study are available within the article and its Supplementary Information files and from the corresponding author upon request.
14

RESULTS.
Genetic locus with genome-wide association with arterial stiffness. DB129663 is a 542bp noncoding transcript (PhyloSCF non-coding score based on small open reading frame analysis is -173.3629; transcripts with a score < 41 are considered non-coding 20 , LNCipedia) that partially overlaps a BCL11B enhancer in the genetic locus on chromosome 14 with genome-wide association with elevated PWV 1 . A detailed analysis revealed that DB129663 gene contains a highly conserved 550bp sequence (> 95% homology among species), where the highest significant SNP variant associated with increased PWV (rs1381289) is located. By using BLAST, we located this highly conserved 550bp sequence in the mouse genome and identified AI060616 as a putative DB129663 homolog in the mouse genome. Considering that enhancer-associated lncRNAs are generally transcribed from the active enhancer they overlap 21 , we used DB129663/AI060616 expression as a surrogate marker of a functionally active BCL11B enhancer in aortic tissue. We is co-regulated with the 3'-BCL11B enhancer to transcriptionally regulate BCL11B expression.
Bcl11b is expressed in the VSM and is down-regulated in animal models of arterial stiffness.
We next sought to determine whether Bcl11b, a downstream target of the DB129663/enhancer locus with SNP variants associated with arterial stiffness, is present in the vasculature. By using knock-in mice expressing a red fluorescence protein (mTomato) upon removal of BCL11B after tamoxifen administration (ER-Cre-Bcl11b flox/flox -mT knock in mice), we were able to visualize Bcl11b's localization in aortic sections and, specifically, in the tunica media ( Figure 3A , left panels). These findings were confirmed by immunostaining aortic sections with an antibody specific to Bcl11b ( Figure 3A , right panels), with Western blotting of aortas and aortic smooth muscle cells ( Figure 3B ) and with qRT-PCR of human aortas ( Figure 3C ). In addition to the aorta, Bcl11b was visualized in VSM of arteries and arterioles in heart, lung and kidney (Supplemental Figure 4A ). However, two-week ang II treatment was sufficient to cause aortic aneurysms in BSMKO mice (5 out of 7, ∼ 70% incidence and 2 out of 7 died due to aneurysm rupture) in suprarenal and/or thoracic aortic regions, compared to angII-treated WT mice, none of which developed aortic dilatations in the same period (0 out of 7; Figure 8A ). TUNEL staining of aortic sections indicated an increased number of apoptotic VSM cells in aneurysmal aortas of angII-treated BSMKO compared to angII-treated WT mice ( Figure 8B ).
VSM Bcl11b regulates actin polymerization and vasodilator-stimulated phosphoprotein
(VASP) phosphorylation at serine 239. Non-muscle actin polymerization in the cytoskeleton contributes to VSM cell cytoskeletal stiffness 25 and VSM tension development independently of myosin light chain 20 (MCL 20 ) phosphorylation and cross-bridge cycles 25 . Therefore, we next examined whether cytoskeletal actin polymerization may have contributed to increased VSM tone and stiffness in BSMKO aortas despite decreases in contractile proteins. We found increased filamentous to glomerular (F/G) actin ratio, indicative of increased actin polymerization, in BSMKO aortas compared to WT, assessed by Western Blot in aortic homogenates ( Figure 9A; ratio of F and G actin bands intensity: 4.82 ± 1.33 A.U. in WT, n=6 vs 9.09 ± 1.02 A.U. in BSMKO, n=7; *, p<0.05).
Vasodilator-stimulated phosphoprotein (VASP) is an important regulator of non-muscle actin polymerization-dependent VSM tone 26 while phosphorylation of VASP at serine 239 (pVASP S239 ) inhibits actin polymerization in VSM cells 27 . Based on our previous findings that increased aortic pVASP S239 is associated with decreased diet-induced arterial stiffness 11 , we next examined whether VASP and pVASP S239 were affected in VSM Bcl11b-deleted aortas thereby regulating cytoskeletal actin assembly. We found that pVASP S239 was dramatically decreased in Figure 4B ), compared to ND-fed mice ( Figure 9D ; WB band intensity: 1.14 ± 0.11
A.U. in ND, n=6 vs 0.46 ± 0.07 A.U. in HFHS, n=10; *, p<0.05).
VASP phosphorylation in VSM cells is finely regulated by protein kinases (PKG, PKA) 28 and phosphatases (PP1, PP2A, PP2B, PP2C) 29 . Of interest, Ca ++ /calmodulin-dependent serinethreonine phosphatase calcineurin (PP2B) has been shown to directly interact with Bcl11b to 20 regulate gene expression in T-cells 30 . Therefore, we examined whether PP2B may be responsible for decreased pVASP S239 levels in BSMKO VSM cells. We found that PP2B protein expression was significantly upregulated in BSMKO VSM cells ( Figure 10A ). In addition, overnight treatment with cyclosporine A, a PP2B inhibitor, restored pVASP S239 levels in BSMKO VSM cells (Figures 10B & 10C ; quantitation in graph), in a dose-dependent manner, indicating that decreased pVASP S239 in BSMKO VSM is dependent mainly on increased PP2B. Moreover, overexpressing Bcl11b in aortic media rings by transient transfection for 3 days was sufficient to significantly restore MYH11, α-SMA, pVASP S239 and decrease PP2B to control levels ( Figure   10D ). Taken together, our data indicate that VSM Bcl11b regulates PP2B-dependent decreases in pVASP S239 associated with increased actin polymerization.
DISCUSSION.
A recent genome-wide association study (GWAS) demonstrated that specific SNPs in the vicinity of the BCL11B genetic locus are associated with increased arterial stiffness and subsequent risk of developing CVD 1 . Interestingly, the highest significant SNP variant (rs1381289) in this "aortic stiffness" locus falls in a highly conserved sequence within a lncRNA (DB129663) which partially overlaps with a BCL11B enhancer. These observations prompted us to examine whether there is a cause-effect relation between Bcl11b and vascular function.
Here we report for the first time that DB129663 and its putative mouse homolog AI060616 are expressed in human and murine aortas, respectively, and that DB129663 downregulation results in ∼ 50% decrease in Bcl11b mRNA, which is consistent with the hypothesis that the BCL11B enhancer region regulates Bcl11b expression at the transcriptional level. These findings suggest that SNP variants in the 3'-BCL11B locus may alter the Bcl11b gene enhancer function 21 and may play a causal role in the pathogenesis of arterial stiffness by regulating Bcl11b expression.
Elevated PWV, the gold standard measure of aortic wall stiffness, strongly associates with adverse cardiovascular outcomes [35] [36] [37] . Despite compelling clinical evidence, cellular and molecular cues of aortic wall stiffening are not fully understood, hampering the discovery of therapeutic targets that can slow or reverse arterial stiffness and thus decrease the risk of developing CVD.
Our study demonstrates for the first time that Bcl11b, previously known for its role in T lymphocyte 8 Interestingly, a major Bcl11b interacting protein, COUP-TFII, is required for atria and blood vessel development during embryogenesis 38 . However, until now, a role of Bcl11b in the adult cardiovascular system was unknown. Our novel findings with a mTomato-tagged Bcl11b reporter mouse, further confirmed by qRT-PCR in human and murine aortas and Western Blotting and immunohistochemistry in murine aortas and VSM cells, clearly indicate that Bcl11b is expressed in the VSM of the aortic wall and in arteries and arterioles of heart, lung and kidney.
Importantly, we uncovered a pivotal role of VSM Bcl11b in the regulation of VSM contractile and cytoskeletal filaments, which form a coordinated system to efficiently transduce contractile forces to the extracellular matrix and among adjacent VSM cells, thereby sustaining aortic wall mechanics and compliance.
In response to pressure or mechanical stretch, thin filament dynamic assembly, namely non-muscle actin polymerization, become a major determinant of VSM contraction and basal tone 25, 39 , independently of myosin light chain 2 phosphorylation and actino-myosin cross-bridges cycles 40, 41 . Dynamic actin cytoskeletal rearrangements can sustain VSM force generation and cytoskeletal stiffness to maintain vessel diameter in response to wall tension or stretch 42 , as it may occur in the aorta exposed to cyclic strain induced by cardiac contraction, particularly in the proximal regions. Therefore, an increase in baseline filamentous/glomerular (F/G) actin ratio, indicative of increased actin polymerization ( Figure 9A ), is consistent with increased baseline force and wall tension in BSMKO aortas ( Figure 7A ) and increased PWV in BSMKO mice ( Figure   7B ) compared to WT controls.
Vasodilator-stimulated phosphoprotein (VASP) has emerged as an important mediator of actin polymerization-dependent VSM force generation. Specifically, we 26 and others [43] [44] [45] have previously shown that VASP interacts with α-actinin, vinculin, zyxin and other components of thin filament assembly at focal adhesion and dense bodies, which are important sites of VSM contractile filaments attachment, cell-cell interactions and cell adhesion to the extracellular matrix, thereby contributing to VSM tone and stiffness independently of myosin light chain 2 phosphorylation. The drug cytochalasin D, commonly used to block actin polymerization in a variety of cell types, is known to interfere with VASP localization to nascent F-actin filaments 46 underscoring the pivotal role of VASP in cytoskeletal actin rearrangement. Moreover, VASP overexpression has been shown to induce F-actin assembly 47 ; in contrast, VASP phosphorylation at serine 239 is sufficient to inhibit actin filament polymerization 27 .
Based on these and our previous findings that increased aortic pVASP S239 is associated with decreased diet-induced arterial stiffness 11 , we measured pVASP S239 and total VASP in aortas of mice lacking Bcl11b in VSM to assess whether these mechanisms could similarly occur in stiff aortas of BSMKO mice. We found that baseline pVASP S239 was dramatically decreased in BSMKO aortas and VSM cells, while total VASP remained unchanged. Moreover, in accordance with our previous work, stiff aortas of high fat, high sucrose-fed mice have decreased pVASP Overall, our data suggest that VSM Bcl11b is required to regulate VASP-mediated actin polymerization and basal VSM tone in the aorta. Increased actin polymerization and associated increases in baseline wall tension and stiffness in BSMKO aortas, may be a compensatory mechanism required to sustain aortic wall mechanics in the settings of drastically decreased contractile elements MYH11 and α-SMA (see Figure 11 for a graphical summary).
Considering that Bcl11b interacts directly with the Ca ++ /calmodulin serine-threonine phosphatase calcineurin (also known as protein phosphatase 2B, PP2B) in T-cells 30 , we explored the possibility that a similar interaction could occur in VSM and may contribute to decreased pVASP S239 when VSM Bcl11b is deleted. Baseline PP2B levels were significantly increased and showed an inverse correlation with pVASP S239 in BSMKO VSM cells. Moreover, treatment with a calcineurin inhibitor, cyclosphorine A, was able to partially restore decreased pVASP S239 in BSMKO VSM cells. Although we did not determine the contribution of other possible kinases or phosphatases to the regulation of VASP phosphorylation in BSMKO aortas, our data strongly suggest that (1) VSM Bcl11b is a transcriptional repressor of PP2B in the aorta; and (2) Bcl11b-dependent PP2B is a primary regulator of VASP phosphorylation at serine 239 in VSM cells.
Bcl11b is a zinc finger protein known to bind G/C-rich DNA elements 5 some of which are negative-acting cis-elements crucial to regulate VSM de-differentiation 48, 49 . Therefore, it is reasonable to speculate that Bcl11b transcriptionally regulates MYH11, α-SMA and calcineurin by directly binding to their promoter regions, possibly by recruiting the histone deacetylase sirtuin-1 (SirT1) 50 to epigenetically regulate VSM gene promoters, although the detailed mechanisms remain to be determined. Our findings that transiently overexpressing Bcl11b in aorta for 3 days was sufficient to reverse the decrease in MYH11, α-SMA, pVASP S239 and the increase in calcineurin expression ( Figure 10D ) are consistent with this hypothesis.
Despite having profound effects on the aorta, lack of VSM Bcl11b did not affect blood pressure regulation in BSMKO mice as baseline and angiotensin II-hypertension were comparable with WT mice suggesting a dispensable role of Bcl11b in the regulation of VSM tone in resistance vessels. Mice were 2 months old at the time of BP measurements; therefore, we cannot exclude that detectable effects of VSM Bcl11b deletion on BP regulation may become apparent at later time points with advancing age. A differential role of Bcl1b in VSM of large versus small arteries could also be explained by the fact that smooth muscle along the adult vascular tree is not homogeneous but rather a mosaic of phenotypically and functionally distinct smooth muscle cell types 54 . Elegant lineage mapping studies have demonstrated that smooth muscle of proximal regions of the aorta, which are the most susceptible to vascular stiffening, namely the outflow tract, innominate, common carotid and subclavian arteries, but not the smooth muscle of resistance vessels, developmentally originates from the cranial neural crest 55 . Considering that Bcl11b is highly expressed and required for neuronal development during embryogenesis 9, 10 , it is reasonable to speculate that Bcl11b, possibly via COUP-TFII, may be a common regulator of lineage 25 commitment for VSM and neurons in early embryonic development. Alternatively, a common progenitor neuronal stem cell expressing Bcl11b may be crucial for smooth muscle cell lineage commitment, including the expression of contractile markers, MYH11 and α-SMA, in large vessels during fetal development. In vivo lineage tracing studies, such as LacZ reporter mice, will be necessary to fully elucidate Bcl11b expression patterns during gestation and in the adult vascular tree.
Interestingly, despite the lack of effect of Bcl11b deletion in VSM on baseline blood pressure or ang II-hypertension, two week infusions with ang II were sufficient to induce thoracic or suprarenal aortic aneurysms in 5 out of 7 (∼ 70%) ang II-infused BSMKO mice, as compared to 28 days commonly required to observe suprarenal aortic aneurysms with ang II infusions in experimental models 56 . MYH11 and α-SMA genetic mutations have been causally linked to nonsyndromic aortic aneurysms 57 . Considering that lack of VSM Bcl11b drastically reduced MYH11
and α-SMA expression in BSMKO mice (Figure 6 ), it is plausible that BSMKO mice phenocopy MYH11 and α-SMA genetic mutations predisposing the aortic wall to dilations and tearing, when challenged with increased hemodynamic load induced by ang II-hypertension. In addition, our finding of increased apoptotic VSM cells in aneurysmal aortas of angII-treated BSMKO mice ( Figure 8B ) is consistent with a pro-apoptotic effect of Bcl11b deletion in lymphoblastic T-cells by affecting p53 58 , a pro-apoptotic transcription factor whose uncontrolled activation has been causally linked to aortic aneurysms and dissection 59 . Moreover, lack of VSM Bcl11b may interfere with VSM SirT1 function, a lysine deacetylase known to interact directly with Bcl11b 50 and p53 60 , and that we previously showed being indispensable in the aortic wall to prevent obesityinduced arterial stiffness 11 and angII-induced aortic dissections 12 . Lastly, although the clinical relation between arterial stiffness and aortic aneurysms remains controversial, recent clinical 26 evidence demonstrated a direct correlation between PWV and aneurysm development or progression in individuals genetically predisposed to aortic aneurysm 61, 62 . Therefore, increased aortic stiffness may have contributed to aortic mechanical failure (i.e., aortic dilatations and ruptures) in BSMKO mice when challenged with an increased hemodynamic load (angII-induced hypertension).
In conclusion, our study has uncovered a novel and crucial role for VSM Bcl11b in aortic structural and functional integrity and strongly supports Bcl11b as a potential therapeutic target against arterial stiffness and aortic aneurysms. Further studies in human populations are warranted to establish whether the genotype at the 3'-BCL11B locus may be used as diagnostic biomarker to identify individuals at increased risk of developing arterial stiffness and other vascular diseases. 
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